This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UK Competition Commission retains IMS's undertakings on specialized pharmaceutical data services

( December 23, 2013, 13:23 GMT | Official Statement) -- MLex Summary: The UK Competition Commission has provisionally decided to retain undertakings that IMS Health Incorporated (IMS) offered to obtain merger approval for its acquisition of Pharmaceutical Marketing Services in 1999. The regulator said that despite the publication of NHS prescription data, IMS would still face limited competition in market for the supply of prescription data. Interested persons have until Jan., 23 to submit comments.Full statement follows....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login